sars cov in 3

SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication.

SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

3CLPro-IN-3 (Compound A36) is an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 51.3 nM. It exhibits antiviral activity against human coronaviruses 229E, OC43, and the murine coronavirus MHV.

SARS-CoV-2 nsp13-IN-3 (Compound C3) is a small molecule inhibitor of SARS-CoV-2 non-structural protein 13 (nsp13), targeting nsp13 ssDNA+ATPase with an IC50 of 32 μM.

SARS-CoV-2 3CLpro-IN-3, a SARS-CoV-2 3CLpro inhibitor, demonstrates antiviral, antibacterial, and antifungal properties.

SARS-CoV-2 nsp14-IN-3 (4975) is a potent inhibitor of the N7-Methyltransferase activity of SARS-CoV-2 nonstructural protein 14 (Nsp14), with an IC50 value of 3.5 μM [1].

SARS-CoV-2 3CLpro-IN-25 (compound 56) effectively inhibits the SARS-CoV-2 3CLpro enzyme, exhibiting an IC50 value of 70 nM, and demonstrates cellular antiviral activity with an EC50 of 3.1 μM.

SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 of 21 nM. It also exhibits robust anti-replicase activity against SARS-CoV-2, with an EC50 of 5 nM.

SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is a conformational inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. It demonstrates good cellular permeability, being able to effectively cross the cell membrane following co-incubation with Vero-E6 cells.

SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor of SARS-CoV-2 3CLpro, exhibiting an IC50 value of 0.018 μM.

SARS-CoV-2 3CLpro-IN-30 (compound 29) is a potent inhibitor of the SARS-CoV-2 3CL protease (SARS-CoV-2 3CLpro), with an IC50 of 0.04 μM and an EC50 of 0.3 μM.

SARS-CoV-2 3CLpro-IN-32 (compound B16) is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, with an IC50 of 0.109 μM. It also demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM.

SARS-CoV-2 3CLpro-IN-22 (Compound 17) is an inhibitor of cathepsin L (CTSL) with an IC50 value of 32.5 nM, useful in research related to the SARS-CoV-2 virus.

SARS-CoV-2 3CLpro-IN-23 (CompoundCd3) is a compound isolated from flat lemon (Citrus depressa). It exhibits strong inhibitory activity against the SARS-CoV-2 spike protein with a KD of 0.79 μM. This compound can bind to key amino acid residues, disrupting the formation of the spike protein and h-ACE2 complex.

PROTACSARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity by degrading the main protease (Mpro) of human coronaviruses (HCoV) with a DC50 of 27 μM. It effectively inhibits viral replication, with EC50 values of 4.6 μM for HCoV-229E and HCoV-OC43, and 0.71 μM for SARS-CoV-2.

SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent inhibitor of the SARS-CoV-2 3CL protease (3CLpro) with an IC50 value of 37.33 nM. It effectively obstructs the cleavage of viral polyproteins and subsequently inhibits the replication of SARS-CoV-2. This compound holds promise for research into SARS-CoV-2 infections.

SARS-CoV-2 nsp3-IN-2 is a SARS-CoV-2 nsp3 macrodomain (Mac1) inhibitor with an IC50 value of 180 μM and functions as an ADP-ribosylhydrolase critical for coronavirus replication and pathogenesis. SARS-CoV-2 nsp3-IN-2 is a small molecule chemical probe useful for viral research[1].

SARS-CoV-2 nsp3-IN-1 (Compound 15c) exhibits significant selectivity for coronavirus macrodomains, particularly SARS-CoV-2 Mac1, and can inhibit Mac1 ADP-ribosylhydrolase activity with an IC50 of 6.1 μM [1].

SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS-CoV-2 3CLpro with antiviral, antibacterial, and antifungal properties.

SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair, demonstrating significant research potential for SARS-CoV-2 disease.

SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a highly potent inhibitor specifically designed to target and inhibit the activity of SARS-CoV-2 3CL pro, a cysteine protease found in the main coronaviruses. This enzyme is a promising target for antiviral drug development, positioning SARS-CoV-2 3CLpro-IN-1 as significant for advancing research in infectious diseases [1].

SARS-CoV-2 3CLpro-IN-10(5d) is a potent inhibitor of the SARS-CoV-2 3CL protease with an IC50 value of 190 nM and demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 790 nM for SARS-CoV-1 and 70 nM for MERS-CoV.

SARS-CoV-2 3CLpro-IN-11(11d) is a broad-spectrum antiviral compound that inhibits the SARS-CoV-2 3CL protease with an IC50 of 140 nM, and also exhibits inhibitory activity against SARS-CoV-1 and MERS-CoV with IC50 values of 240 nM and 70 nM, respectively.

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), with potent inhibitory activity (IC50: 3.8 nM) and 9.0% oral bioavailability (BA), used in COVID-19 research [1].